A Phase IIA, Multi-Center, Randomized, Third-Party Unblinded, Adjuvant-Controlled, Multiple-Ascending Dose Safety, Tolerability and Immunogenicity Trial of ACC-001 with QS-21 Adjuvant in Patients with Mild to Moderate Alzheimer's Disease

Study Status: 
Study Description: 

Please click on the study title and see the attached memo.

Study Coordinator(s): 

Martha van der Vliet

Scott McGinnis

Telephone:  617-525-8383

ACC-001 summary for internal use.doc41 KB